Status: Recruiting
Luspatercept for CIA in AML
This study aims to explore the feasibility, safety, and preliminary efficacy of rotegcipipone in the treatment of chemotherapy-inducing anemia in AML with a multicenter, prospective, single-arm trial, providing clinical evidence for subsequent clinical development.
Participants needed: 40
Trial details
Phase: Phase 1, Phase 2Age: 18-60Biological sex: AllType: InterventionalSponsor: Guangdong Second Provincial General HospitalUpdated: Jun 23, 2026Locations: 1
Eligibility criteria
De novo AML patients; [+7]
t-AML/sAML [+11]